Pengcheng Han1, Winnie Liang, Leslie C Baxter, Junxiang Yin, Zhiwei Tang, Thomas G Beach, Richard J Caselli, Eric M Reiman, Jiong Shi. 1. From the Barrow Neurological Institute (P.H., L.C.B., J.Y., Z.T., J.S.), St. Joseph Hospital and Medical Center, Dignity Health Organization, Phoenix; Translational Genomics Research Institute (W.L.), Phoenix, AZ; Department of Neurosurgery (Z.T.), The First Hospital of Kunming Medical University, Kunming, China; Civin Laboratory for Neuropathology (T.G.B.), Banner Sun Health Research Institute, Sun City; Department of Neurology (R.J.C.), Mayo Clinic Arizona, Scottsdale; and Banner Alzheimer's Institute (E.M.R.), Phoenix, AZ.
Abstract
OBJECTIVES: There is growing evidence that pituitary adenylate cyclase-activating polypeptide (PACAP) is associated with Alzheimer disease (AD) pathology in animal models, but human studies are needed. METHODS: We studied the brains of patients with pathologically confirmed late-onset AD and age-matched cognitively normal (CN) subjects to investigate the expression of PACAP messenger RNA (34 AD and 14 CN) and protein (12 AD and 11 CN) in a case-control study. RESULTS: We report that PACAP levels are reduced in multiple brain regions, including the entorhinal cortex, the middle temporal gyrus, the superior frontal gyrus, and the primary visual cortex. This reduction is correlated with higher amyloid burden (CERAD plaque density) in the entorhinal cortex and superior frontal gyrus but not in the primary visual cortex, a region spared in most cases of AD. PACAP expression is lower in advanced Braak stages (V and VI) than in moderate stages (III and IV). Increased PACAP levels are associated with decreased scores on the Dementia Rating Scale, a global cognitive measure. Finally, CSF levels paralleled brain levels in AD but not in Parkinson dementia or frontotemporal dementia brains. CONCLUSIONS: The close relationship between PACAP reduction and the severity of AD pathology suggests that downregulation of PACAP may contribute to AD pathogenesis.
OBJECTIVES: There is growing evidence that pituitary adenylate cyclase-activating polypeptide (PACAP) is associated with Alzheimer disease (AD) pathology in animal models, but human studies are needed. METHODS: We studied the brains of patients with pathologically confirmed late-onset AD and age-matched cognitively normal (CN) subjects to investigate the expression of PACAP messenger RNA (34 AD and 14 CN) and protein (12 AD and 11 CN) in a case-control study. RESULTS: We report that PACAP levels are reduced in multiple brain regions, including the entorhinal cortex, the middle temporal gyrus, the superior frontal gyrus, and the primary visual cortex. This reduction is correlated with higher amyloid burden (CERAD plaque density) in the entorhinal cortex and superior frontal gyrus but not in the primary visual cortex, a region spared in most cases of AD. PACAP expression is lower in advanced Braak stages (V and VI) than in moderate stages (III and IV). Increased PACAP levels are associated with decreased scores on the Dementia Rating Scale, a global cognitive measure. Finally, CSF levels paralleled brain levels in AD but not in Parkinson dementia or frontotemporal dementia brains. CONCLUSIONS: The close relationship between PACAP reduction and the severity of AD pathology suggests that downregulation of PACAP may contribute to AD pathogenesis.
Authors: Zhi-Liang Wu; John R Ciallella; Dorothy G Flood; Teresa M O'Kane; Donna Bozyczko-Coyne; Mary J Savage Journal: Neurobiol Aging Date: 2005-05-31 Impact factor: 4.673
Authors: Winnie S Liang; Travis Dunckley; Thomas G Beach; Andrew Grover; Diego Mastroeni; Keri Ramsey; Richard J Caselli; Walter A Kukull; Daniel McKeel; John C Morris; Christine M Hulette; Donald Schmechel; Eric M Reiman; Joseph Rogers; Dietrich A Stephan Journal: Physiol Genomics Date: 2008-02-12 Impact factor: 3.107
Authors: N Cabezas-Llobet; L Vidal-Sancho; M Masana; A Fournier; J Alberch; D Vaudry; X Xifró Journal: Mol Neurobiol Date: 2018-03-10 Impact factor: 5.590
Authors: M Feher; B Gaszner; A Tamas; A L Gil-Martinez; E Fernandez-Villalba; M T Herrero; D Reglodi Journal: Neurotox Res Date: 2017-12-11 Impact factor: 3.911
Authors: Pengcheng Han; Richard J Caselli; Leslie Baxter; Geidy Serrano; Junxiang Yin; Thomas G Beach; Eric M Reiman; Jiong Shi Journal: JAMA Neurol Date: 2015-03 Impact factor: 18.302
Authors: Thomas G Beach; Charles H Adler; Lucia I Sue; Geidy Serrano; Holly A Shill; Douglas G Walker; LihFen Lue; Alex E Roher; Brittany N Dugger; Chera Maarouf; Alex C Birdsill; Anthony Intorcia; Megan Saxon-Labelle; Joel Pullen; Alexander Scroggins; Jessica Filon; Sarah Scott; Brittany Hoffman; Angelica Garcia; John N Caviness; Joseph G Hentz; Erika Driver-Dunckley; Sandra A Jacobson; Kathryn J Davis; Christine M Belden; Kathy E Long; Michael Malek-Ahmadi; Jessica J Powell; Lisa D Gale; Lisa R Nicholson; Richard J Caselli; Bryan K Woodruff; Steven Z Rapscak; Geoffrey L Ahern; Jiong Shi; Anna D Burke; Eric M Reiman; Marwan N Sabbagh Journal: Neuropathology Date: 2015-01-26 Impact factor: 1.906
Authors: Junxiang Yin; Eric M Reiman; Thomas G Beach; Geidy E Serrano; Marwan N Sabbagh; Megan Nielsen; Richard J Caselli; Jiong Shi Journal: Neurology Date: 2020-05-26 Impact factor: 11.800
Authors: Pengcheng Han; Megan Nielsen; Melissa Song; Junxiang Yin; Michele R Permenter; Julie A Vogt; James R Engle; Brittany N Dugger; Thomas G Beach; Carol A Barnes; Jiong Shi Journal: Front Aging Neurosci Date: 2017-06-12 Impact factor: 5.750
Authors: Dora Reglodi; Adel Jungling; Rémi Longuespée; Joerg Kriegsmann; Rita Casadonte; Mark Kriegsmann; Tamas Juhasz; Sebastian Bardosi; Andrea Tamas; Balazs Daniel Fulop; Krisztina Kovacs; Zsuzsanna Nagy; Jason Sparks; Attila Miseta; Gabriel Mazzucchelli; Hitoshi Hashimoto; Attila Bardosi Journal: J Pathol Date: 2018-07-04 Impact factor: 7.996